Bisphosphonates

PreclinicalSmall molecule

VVanderbilt-Ingram Cancer Center

Bisphosphonates is one of 36 small molecule programs targeting Osteogenesis Imperfecta. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteogenesis ImperfectaActive, not recruiting

Adverse EffectActive, not recruiting

Osteogenesis ImperfectaPreclinical

Active, not recruiting

Adverse EffectPreclinical

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Adverse Effect

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 2

Indocin

CCosette Pharmaceuticals, Inc.

Approved

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Pulmicort

SSalix

Approved

1 5

Oxycontin

PProtega

Approved

1 6

Eldepryl

QQuagen

Approved

1 7

Bayer Aspirin

Bayer

Preclinical

1 8

Ultram

WWim Janssens

Preclinical

1 9

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Recruiting

Osteogenesis Imperfecta

NCT04115774

Clinical

Trials by Indication[1]

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Women1 trial

Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women

Completed·—··NCT02115490·60 enrolled

Osteoporosis1 trial

Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis

Completed·TTuen Mun Hospital·Phase 4·NCT01465568·40 enrolled

Adverse Effect1 trial

A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients

Unknown status·SSun Yat-sen University··NCT03543072·2,000 enrolled

Osteogenesis Imperfecta1 trial

Registry of Osteogenesis Imperfecta

Recruiting·LLuca Sangiorgi··NCT04115774·5,000 enrolled

2 more indications

Vertebral Compression Fracture1 trial

Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

Withdrawn·UUniversity of California, Davis·Phase 4·NCT03651804

Unspecified1 trial

The Effect of Long-term Use of Bisphosphonates on Femur Morphology

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06621069·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Bisphosphonates. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonates compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonates. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt-Ingram Cancer Center

Bisphosphonates

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Minimal Residual Disease1 trial

Women1 trial

Osteoporosis1 trial

Adverse Effect1 trial

Osteogenesis Imperfecta1 trial

Vertebral Compression Fracture1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News